Cardica Inc. (NASDAQ:DXTR) has been assigned a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and one has issued a strong buy rating on the company.

Brokers have set a 1 year consensus target price of $8.50 for the company and are predicting that the company will post ($0.48) EPS for the current quarter, according to Zacks. Zacks has also given Cardica an industry rank of 91 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research raised Cardica from a “hold” rating to a “buy” rating and set a $2.50 price target for the company in a report on Friday, August 12th.

Shares of Cardica (NASDAQ:DXTR) traded up 0.5179% during midday trading on Wednesday, reaching $1.9601. 7,644 shares of the company’s stock traded hands. Cardica has a 52 week low of $1.10 and a 52 week high of $4.30. The stock’s 50 day moving average is $2.15 and its 200-day moving average is $2.67. The company’s market capitalization is $17.44 million.

Cardica (NASDAQ:DXTR) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by $0.01. Cardica had a negative return on equity of 688.02% and a negative net margin of 394.39%. On average, analysts forecast that Cardica will post ($1.53) earnings per share for the current fiscal year.

Cardica Company Profile

Dextera Surgical Inc, formerly Cardica, Inc, is focused on the commercialization and development of microcutter product line intended for use by surgeons. The Company is engaged in commercializing and developing MicroCutter XCHANGE 30 based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.

5 Day Chart for NASDAQ:DXTR

Get a free copy of the Zacks research report on Cardica (DXTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cardica Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardica Inc. and related companies with MarketBeat.com's FREE daily email newsletter.